Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Spencer Ellis"'
Autor:
Chrissy Bolton, Yifan Chen, Rachel Hawthorne, Ianthe R. M. Schepel, Elinor Harriss, Silke C. Hofmann, Spencer Ellis, Alexander Clarke, Helena Wace, Blanca Martin, Joel Smith
Publikováno v:
Drugs in R&D, Vol 20, Iss 4, Pp 319-330 (2020)
Abstract Background Subacute cutaneous lupus erythematosus (SCLE) lacks consensus diagnostic criteria and the pathogenesis is poorly understood. There are increasing reports of SCLE induced by monoclonal antibodies (mAbs), but there are limited data
Externí odkaz:
https://doaj.org/article/675cad814f1e48b8a7f8324f8f8d3305
Autor:
Caden LaFontaine, Bailey Tallman, Spencer Ellis, Trevor Croteau, Brandon Torres, Sabrina Hernandez, Diego Cristancho Guerrero, Jessica Jaksik, Drue Lubanski, Roland Allen
Publikováno v:
Universe, Vol 7, Iss 8, p 270 (2021)
A recently proposed dark matter WIMP (weakly interacting massive particle) has only second-order couplings to gauge bosons and itself. As a result, it has small annihilation, scattering, and creation cross-sections, and is consequently consistent wit
Externí odkaz:
https://doaj.org/article/1a604b12692d49ac982cdbce21524214
Publikováno v:
Rheumatology. 61
Background/Aims With biological agents used for inflammatory arthritis (IA) for over 20 years and the more recent addition of targeted synthetic agents, it is no surprise that pre-screening has evolved as we continually learn about these drugs. The B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc3b7df35ebda9b457ebef23fc310ea1
https://doi.org/10.1093/rheumatology/keac133.056
https://doi.org/10.1093/rheumatology/keac133.056
Publikováno v:
British Journal of Hospital Medicine. 81:1-4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fa3456dd2eea2b2f403d25a7f0c8fcf
https://doi.org/10.12968/hmed.2020.0049
https://doi.org/10.12968/hmed.2020.0049
Autor:
Spencer Ellis, Qurat Ul Ain Amjad
Publikováno v:
Rheumatology Advances in Practice
Case report - Introduction Rheumatic disease occurring as a paraneoplastic manifestation such as dermatomyositis is well recognised, whilst the symptoms of cancer may frequently mimic the presentations of common rheumatic disorders. It is essential t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bfbbfdbd410821237d5671c1f91b32a
http://europepmc.org/articles/PMC8524155
http://europepmc.org/articles/PMC8524155
Autor:
Qurat Ul Ain Amjad, Spencer Ellis
Publikováno v:
Rheumatology Advances in Practice. 5
Case report - Introduction Antiphospholipid Syndrome (APS) is an autoimmune condition manifested by vascular thrombosis with or without pregnancy related morbidities. APS classification criteria require detection of persistent antibodies: Anti-Cardio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6afee07c8311419ca261ddde37af471
https://doi.org/10.1093/rap/rkab067.021
https://doi.org/10.1093/rap/rkab067.021
Autor:
Spencer Ellis, Qurat Ul Ain Amjad
Publikováno v:
Rheumatology Advances in Practice
Case report - Introduction Rheumatoid arthritis (RA) is an autoimmune inflammatory arthropathy with systemic manifestations. It is 4-times more common in females. RA is recognised to induce bone loss and decrease in bone mineral density (BMD). Manage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e53e58b7472d1508b63f2f44dffcd8cc
http://europepmc.org/articles/PMC8524168
http://europepmc.org/articles/PMC8524168
Publikováno v:
Rheumatology Advances in Practice. 5
Case report - Introduction Catastrophic antiphospholipid syndrome (CAPS) is a rare, life-threatening disease occurring in up to 1% of antiphospholipid syndrome (APS) cases. It was first defined in 1992 and remains a difficult to treat entity with a m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cec1c91d939461c8211361c60ef37c65
https://doi.org/10.1093/rap/rkab067.022
https://doi.org/10.1093/rap/rkab067.022
Publikováno v:
Rheumatology. 60
Background/Aims Disease-modifying anti-rheumatic drugs (DMARDs) require blood monitoring as recommended by the British Society for Rheumatology guidelines. Deranged liver function tests are a common abnormality, and when a significant transaminitis o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b233cd48d55cc4e7af4e99ec9552284
https://doi.org/10.1093/rheumatology/keab247.034
https://doi.org/10.1093/rheumatology/keab247.034
Autor:
Alexander J. Clarke, Silke C. Hofmann, Helena Wace, Elinor Harriss, Blanca Martin, Ianthe R. M. Schepel, Chrissy Bolton, Joel Smith, Yifan Chen, Rachel Hawthorne, Spencer Ellis
Publikováno v:
Drugs in R&D, Vol 20, Iss 4, Pp 319-330 (2020)
Drugs in R&D
Drugs in R&D
Background Subacute cutaneous lupus erythematosus (SCLE) lacks consensus diagnostic criteria and the pathogenesis is poorly understood. There are increasing reports of SCLE induced by monoclonal antibodies (mAbs), but there are limited data on the ae
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d316d34c54b02d6e9b93c7755c30e38
https://www.repository.cam.ac.uk/handle/1810/328375
https://www.repository.cam.ac.uk/handle/1810/328375
